Intermittent infusions of zoledronic acid are as effective as daily bisphosphonates in increasing bone mineral density in port-menopausal women.

R. Shmerling,S. Goldring

2003-03-01

Clinical and Experimental Rheumatology

Abstract:Aim Zoledronic acid (ZA) is a potent bisphosphonate, its infusions having been shown to be effective in the treatment of cancer-related hypercalcemia. In order to investigate the effect of ZA on bone mineral density (BMD) in postmenopausal women with low BMD, a one-year multicentre, randomized, double-blind, placebo controlled trial was conducted. Lumbar BMD was the primary end point of the study. Methods 351 post-menopausal women with spine BMD at least 2.0 SD below the T score and no more than one vertebral fracture at screening, who had entered menopause at least 5 years before the beginning of the study, were enrolled at 24 centers in 10 countries. A total of 316 women completed the study, 35 having withdrawn for personal reasons or adverse events. All women received a calcium supplement of 1 g per day. At the beginning of the study the women we re assigned to receive one of six treatments regimens in a double-blinded fashion. Three groups received ZA by intravenous (IV) infusions every 3 months in doses of 0.25 mg (60 women), 0.5 mg (58 women) or 1 mg (53 women). One group received a total annual dose of 4 mg as a single dose at the beginning of the trial (60 women) and another group received a total annual dose of 2 mg each, one at baseline and the other after 6 months (60 women). The sixth group received only placebo (saline) (59 women). To maintain the blinding, all women received an IV infusion of either zoledronic acid or placebo every 3 months. Lumbar spine (L1-L4), non-dominant proximal femur and forearm, and total body BMD were measured by dual-energy x-ray absorptiometry (DEXA) at baseline, and at 6, 9, and 12 months. Biochemical marke rs of bone fo rm ation (seru m bone alkaline phosphatase and osteocalcin) and resorption (urinary N-telopeptide and serum C-telopeptide) were also measured at baseline and at 6, 9, and 12 months. Results Throughout the study all groups receiving ZA showed a progressive increase in lumbar BMD which was significantly higher than in the placebo group (P < 0.001). No difference was found among the ZA groups. At 12 months the mean lumbar BMD in the groups receiving ZA was 4.3-5.1% higher than in the placebo group. Accordingly, mean BMD values for the femoral neck were 3.1-3.5 times higher than those in the placebo group (P < 0.001). In addition, mean values for the distal radius and total body BMD were significantly higher in the ZA than in the placebo groups. Biochemical marke rs of bone re s o rption decreased signifi c a n t ly in all ZA groups with respect to the placebo group (P < 0.01 for all c o m p a risons). No diffe rence was found among the ZA groups. Biochemical markers of bone formation showed similar response. The suppression persisted at 12 months with all the doses (P < 0.001). The rates of adverse effects were similar for all ZA groups and higher in the treated than in the placebo groups (rates of 45-67% vs 27%). In the ZA groups the most common adverse events were myalgia, fever and nausea, generally mild and occurring after the first ZA infusion. Five women withdrew from the study due to drug-related side events, all experienced after the first infusion of ZA. These withdrawals were not dose-related. Symptoms at the infusion site were rare in all the groups. Conclusions Oral bisphosphonates are effective in managing osteoporosis, but they must be administered on an empty stomach, often inducing gastrointestinal side effects and reducing the compliance of the patients. Such problems should be completely solved with the use of IV ZA. Intermittent IV admini s t ration of the potent bisphosphonate ZA produce an increase in lumbar, femural and total body BMD and effects on bone biochemical markers comparable to those seen with daily oral bisphosphonates, which have been proven to be effective in reducing osteoporotic fractures. This suggests that semi-annual or annual infusion of ZA might be an effect ive therapy both for tre ating and preventing post-menopausal osteoporosis, with a significant reduction in the direct and indirect costs of osteoprotective therapies.